Reader Remarks on:

Bleeding Risks with Triple Antithrombotic Therapy, Quantified

Woest study in 2012 ESC congress
WOEST findings

Woest study in 2012 ESC congress

Jean-Pierre USDIN, American Hospital of Paris, 4 Oct 2012 4:38 PM EST

Competing interests: None declared

Specialty: Cardiovascular Disease

I do not precisely understand what Dr Herrmann means in the sentence "but no good studies of the combinations exist." One study on the combination Warfarin + Clopidogrel VS Warfarin+Aspirin+Clopidogrel was the subjet of the recent WEOST study, which showed definitly less bleeding in the case of patient suffering from AF + ACS treated with double therapy compared with triple treatment. may I have some explanation? thank you and sincerely dr Usdin Paris France.

WOEST findings

Howard C. Herrmann, University of Pennsylvania, 5 Oct 2012 2:06 PM EST

Competing interests: None declared

Specialty: Interventional Cardiology

Dear Dr. Usdin: Thank you for your comment. The WOEST study has only been presented in preliminary form and has not yet been published in a peer-reviewed journal. It certainly adds to our understanding of this issue. However, it is a relatively small study (<300 pts per group) and is likely underpowered for many important endpoints (such as stent thrombosis).

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Remark subject:*

Your remark:*

Fields marked with an * are required.

Name as you'd like it to appear:
First & middle initial:*

Last:*

Email address (will not
be published):*

Professional specialty:*

Place of work (optional):

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

No competing interests

Or, the following competing interests (for example, financial stakes or professional relationships):

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?